Tumor Biology

, Volume 34, Issue 4, pp 2293–2298 | Cite as

RETRACTED ARTICLE: Associations of three common polymorphisms in CD95 and CD95L promoter regions with gastric cancer risk

  • Fan Li
  • Yuliang Liu
  • Tao Fu
  • Weidong Tong
  • Anping Zhang
Research Article

Abstract

There are many studies performed to assess the associations of CD95 A670G and G1377A polymorphisms with gastric cancer, and the association of CD95L T844C polymorphism with gastric cancer risk, but the data are remaining controversial. To get a comprehensive assessment of the association above, we performed a meta-analysis of published studies. PubMed, Embase, Web of Science, and Wanfang Medicine databases were searched for eligible studies. There were eight studies including 3,790 subjects on CD95 A670G polymorphism, eight studies including 4,563 subjects on CD95 G1377A polymorphism, and eight studies including 4,563 subjects on CD95L T844C polymorphism. Overall, CD95 G1377A polymorphism was associated with a significantly increased risk of gastric cancer (for AA versus GG: odds ratio (OR) = 1.24, 95 % confidence interval (95 % CI) = 1.02–1.52, P = 0.030; for AA versus GG + GA: OR = 1.27, 95 % CI = 1.05–1.53, P = 0.012). However, there were no associations of CD95 A670G and CD95L T844C polymorphisms with gastric cancer. Subgroup analysis by ethnicity found similar associations in Asians, but the associations in Caucasians were still unclear owing to the lack of relevant data. Therefore, the outcomes of this meta-analysis show that there is a significant association between CD95 G1377A polymorphism and risk of gastric cancer.

Keywords

CD95 CD95L Gastric cancer Meta-analysis 

Notes

Acknowledgments

This work was supported by the General program of National Natural Science Foundation of China (no. 81100259, 81000898, and 81201841) and CSTC (2011jjA055) and Innovation Fund 2010XQN31.

Conflicts of interest

None

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Tan IB, Ng I, Tai WM, Tan P. Understanding the genetic basis of gastric cancer: recent advances. Exp Rev Gastroenterol Hepatol. 2012;6:335–41.CrossRefGoogle Scholar
  3. 3.
    Saeki N, Ono H, Sakamoto H, Yoshida T. Genetic factors related to gastric cancer susceptibility identified using a genome-wide association study. Cancer Sci. 2013;104:1–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Haas SL, Ye W, Lohr JM. Alcohol consumption and digestive tract cancer. Curr Opin Clin Nutr Metab Care. 2012;15:457–67.CrossRefPubMedGoogle Scholar
  5. 5.
    Selgrad M, Bornschein J, Rokkas T, Malfertheiner P. Helicobacter pylori: gastric cancer and extragastric intestinal malignancies. Helicobacter. 2012;17 Suppl 1:30–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Cullen SP, Henry CM, Kearney CJ, Logue SE, Feoktistova M, Tynan GA, Lavelle EC, Leverkus M, Martin SJ. Fas/CD95-induced chemokines can serve as “find-me” signals for apoptotic cells. Mol Cell. 2013. doi: 10.1016/j.molcel.2013.01.025
  7. 7.
    Passadaki T, Asimakopoulos B, Zeginiadou T, Nikolettos N. Soluble fas and fas ligand levels in seminal plasma: association with basic parameters of semen analysis. In Vivo. 2013;27:285–7.PubMedGoogle Scholar
  8. 8.
    Bossaller L, Chiang PI, Schmidt-Lauber C, Ganesan S, Kaiser WJ, Rathinam VA, et al. Cutting edge: FAS (CD95) mediates noncanonical IL-1beta and IL-18 maturation via caspase-8 in an RIP3-independent manner. J Immunol. 2012;189:5508–12.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kutumova E, Zinovyev A, Sharipov R, Kolpakov F. Model composition through model reduction: a combined model of CD95 and NF-kappaB signaling pathways. BMC Syst Biol. 2013;7:13.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Karimi MY, Kapoor V, Sharma SC, Das SN. Genetic polymorphisms in FAS (CD95) and FAS ligand (CD178) promoters and risk of tobacco-related oral carcinoma: gene–gene interactions in high-risk Indians. Cancer Invest. 2013;31:1–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Ikehara SK, Ikehara Y, Matsuo K, Hirose K, Niwa T, Ito H, et al. A polymorphism of C-to-T substitution at -31 IL1B is associated with the risk of advanced gastric adenocarcinoma in a Japanese population. J Hum Genet. 2006;51:927–33.CrossRefPubMedGoogle Scholar
  12. 12.
    Hsu PI, Lu PJ, Wang EM, Ger LP, Lo GH, Tsay FW, et al. Polymorphisms of death pathway genes FAS and FASL and risk of premalignant gastric lesions. Anticancer Res. 2008;28:97–103.PubMedGoogle Scholar
  13. 13.
    Wang M, Wu D, Tan M, Gong W, Xue H, Shen H, et al. FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in southern china. Biochem Genet. 2009;47:559–68.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhou RM, Wang N, Chen ZF, Duan YN, Sun DL, Li Y. Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma. J Gastroenterol Hepatol. 2010;25:555–61.CrossRefPubMedGoogle Scholar
  15. 15.
    Kupcinskas J, Wex T, Bornschein J, Selgrad M, Leja M, Juozaityte E, et al. Lack of association between gene polymorphisms of angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians. BMC Med Genet. 2011;12:112.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Liu L, Wu C, Wang Y, Zhong R, Wang F, Zhang X, et al. Association of candidate genetic variations with gastric cardia adenocarcinoma in Chinese population: a multiple interaction analysis. Carcinogenesis. 2011;32:336–42.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhang MJ, Ma L, Xu CQ, Wang Y. The relationship between fas-670 and fasl-844 gene polymorphism and the susceptibility to gastric cancer. Journal of Shandong University (Health Science). 2011;49:106–9.Google Scholar
  18. 18.
    Zhang W, Li C, Wang J, He C. Functional polymorphisms in FAS/FASL system contribute to the risk of occurrence but not progression of gastric cardiac adenocarcinoma. Hepatogastroenterology. 2012;59:141–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRefGoogle Scholar
  20. 20.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedGoogle Scholar
  21. 21.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  22. 22.
    Hu Y, Jin L, Huang X, Geng P. Fas-670 gene polymorphism and gastric cancer risk in Qinghai regions. Shandong Medical Journal. 2011;51:45–6.Google Scholar
  23. 23.
    Zhou R, Wang N, Sun DL, Duan Y, Huo X, Guo J, et al. Correlation of polymorphisms in apoptosis-associated genes FAS and FASL to the risk of gastric cardiac adenocarcinoma. Chinese Journal of Cancer Prevention and Treatment. 2010;17:1609–22.Google Scholar
  24. 24.
    Zhang MJ, Liu CH, Wang WQ, Xu CQ, Chen ZP, Wang YG. Fas-1377 gene polymorphism and susceptibility to gastric cancer. Shandong Medical Journal. 2010;50:36–7.Google Scholar
  25. 25.
    Banzato PC, Daher S, Traina E, Torloni MR, Gueuvoghlanian-Silva BY, Puccini RF, Pendeloski KP, Mattar R. Fas and fas-l genotype and expression in patients with recurrent pregnancy loss. Reprod Sci 2013. doi: 10.1177/1933719113477488
  26. 26.
    Fujikura D, Chiba S, Muramatsu D, Kazumata M, Nakayama Y, Kawai T, et al. Type-I interferon is critical for fasl expression on lung cells to determine the severity of influenza. PLoS One. 2013;8:e55321.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Fan Li
    • 1
  • Yuliang Liu
    • 1
    • 2
  • Tao Fu
    • 1
  • Weidong Tong
    • 1
  • Anping Zhang
    • 1
  1. 1.Department of General Surgery, Institute of Surgery Research, Daping HospitalThird Military Medical UniversityChongqingChina
  2. 2.Department of Respiratory MedicineThe First Affiliated Hospital of Chongqing Medical UniversityChongqingChina

Personalised recommendations